May 25, 2012
Takeda Pharmaceutical announced on May 24 that its European subsidiary Takeda Global Research & Development Centre (Europe) (TGRD Europe) filed a marketing authorization application (MAA) for its dipeptidyl peptidase-4 (DPP-4) inhibitor SYR-322 (alogliptin; brand name in Japan: Nesina) with the...read more